Published in Oncology Business Week, July 23rd, 2006
The new Pharmacor report titled "Breast Cancer" finds that growth in both breast cancer market segments, chemotherapy and hormonal treatments, will be driven by the expansion of established agents, particularly Herceptin and Novartis's Femara (letrozole), from the metastatic into the adjuvant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week